A Phase II Trial of the Super-enhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)

Authors

Nebojsa Skorupan, Mehwish I. Ahmad, Seth M. Steinberg, Jane B. Trepel, Derek Cridebring, Haiyong Han, Daniel D. Von Hoff, Christine Alewine

Trial registration no:
NCT04896073

End points

Primary end point
Disease control rate (CR + PR + SD for ≥16 weeks)

Secondary end points
- Drug safety
- PFS
- OS

Exploratory end points
Serial biopsies to assess effects on:
- Myc expression
- Accessibility of Myc and other superenhancer loci
- Tumor microenvironment – stroma and immune cells
- Post treatment
  - Changes in circulating tumor DNA
  - Circulating immune cell populations

Study design

- Minnelide is a small molecule anti-superenhancer drug that inhibits MYC
- Trial will be conducted using a Simon optimal two-stage phase II trial design
- The first stage will enroll a total of 12 evaluable participants,
- If clinical benefit is shown, the accrual will continue to a total of 25 evaluable participants



- Drug administration for 21 days of a 28-day cycle for 12 cycles until PD or unacceptable toxicity
- Imaging assessment every 2 cycles

Key eligibility criteria



Glossary

ASCP: Adenosquamous carcinoma of the pancreas; PD: progressive disease; CR: Complete response; PR: partial response; SD: stable disease; PFS: Progression free survival; OS: Overall survival; ECOG PS: Eastern Cooperative Oncology Group; RECIST: Response Evaluation Criteria in Solid Tumors; TMB: Tumor mutational burden